Federal award (DEFINITIVE CONTRACT, fiscal year 2023)
Recipient: SPERO THERAPEUTICS, INC.
Awarding agency: Department of Health and Human Services / National Institutes of Health
Funding agency: Department of Health and Human Services / National Institutes of Health
Period of performance: 2021-05-17 to 2026-12-31
Current total value of award: $10501521.27
Description: TO ADVANCE CLINICAL AND NON-CLINICAL DEVELOPMENT OF AN ANTIBIOTIC CANDIDATE.